Fundamentals of Pre-Exposure Prophylaxis [PrEP]

Mechanism of Pharmacological Action

Pre-exposure prophylaxis is a highly effective biomedical strategy based on the preventive administration of antiretroviral drugs to seronegative individuals.

The pharmacological basis lies in the inhibition of the reverse transcriptase enzyme, a mechanism essential for the replication of the human immunodeficiency virus.

When taken properly, active ingredients such as tenofovir disoproxil fumarate combined with emtricitabine accumulate in high concentrations in lymphoid tissues and in the mucous membranes of the genitourinary and anorectal tracts.

When the body comes into contact with viral particles via infected biological fluids, the intracellular metabolites block the conversion of viral RNA into complementary DNA.

This metabolic interruption prevents the virus from integrating its genetic code into the genome of the host’s CD4 T cells.

Without this ability to integrate into chromosomes, the pathogenic particle is unable to replicate or establish latent reservoirs in the immune system and is naturally eliminated by the body’s cleansing mechanisms.

Thus, the constant presence of the drug at tissue barriers forms a highly effective biological shield that halts the primary infection before it becomes systemic.

Population Eligibility Criteria

Prescribing this prophylactic regimen requires a rigorous clinical eva luation aimed at identifying individuals at substantial risk of acquiring the infection.

The essential prerequisite is to confirm the patient’s seronegative status through highly sensitive serological or molecular tests, conclusively ruling out any acute or latent infection.

Eligibility is focused on sexually active individuals who report inconsistent use of mechanical barriers during high-risk encounters, a recent history of sexually transmitted infections, or who have multiple concurrent sexual partners.

Likewise, it is considered a priority indication for individuals in serodiscordant couples where the partner carrying the virus has not yet achieved stable viral suppression in the blood.

During the medical eva luation, healthcare professionals must verify the absence of preexisting renal dysfunction or other metabolic contraindications that would impede the metabolism of antiretroviral compounds.

This selection process is not intended to categorize behaviors, but rather to direct pharmacological resources toward vulnerable biological populations to maximize the int